J&J abandons trial of atopic dermatitis drug
J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.
No Christmas present for Sanofi, as FDA turns down MS drug
FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026.
Biosimilars unlock use of bevacizumab in bowel cancer by NHS
More than 20 years after its approval, NICE has backed the use of bevacizumab as a treatment for colorectal cancer for the first time.
CMS aims for broader GLP-1 access via federal programmes
CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
Sanofi swoops on Dynavax with $2.5bn takeover deal
Sanofi's last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity
The PM Society Careers Event – 18th February 2026
Join us for our popular event to see how your skills and interests could add value to this vital and constantly evolving industry.
Frontiers Health Turns 10
Celebrating a Decade of Innovation and Collaboration in Berlin, November 11–12, 2025 Berlin / November 7th, 2025 | Marking its 10th anniversary,